Shaji K. Kumar, MD, a consultant in the Division of Hematology and a professor of medicine with Mayo Clinic, discusses the evolving role of venetoclax (Venclexta) in relapsed/refractory multiple myeloma.

Although not FDA approved in myeloma, venetoclax has demonstrated activity in patients with relapsed/refractory disease who harbor 11;14 translocations, says Kumar. As such, single-agent venetoclax or venetoclax in combination with dexamethasone could be a valid treatment option for this subgroup of patients who have not responded to other standard combinations, Kumar explains.

Currently, venetoclax in combination with dexamethasone is being evaluated in the randomized phase 3 CANOVA trial (NCT03539744) vs pomalidomide (Pomalyst) and dexamethasone in patients with relapsed/refractory multiple myeloma, concludes Kumar.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Mayo Clinic

Cancer Centers

Partner

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.  



Dr. Kumar on the Evolving Role of Venetoclax in Relapsed/Refractory Multiple Myeloma